金斯瑞生物科技(01548)：CARVYKTI®第四季度产生贸易销售净额约5.55亿美元

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate approximately $555 million in net trade sales for the quarter ending December 31, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected net trade sales for CARVYKTI® are significant, amounting to approximately $555 million [1]